التفاصيل البيبلوغرافية
| العنوان: |
Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study) |
| المؤلفون: |
Decroisette, Chantal, Greillier, Laurent, Curcio, Hubert, Pérol, Maurice, Ricordel, Charles, Auliac, Jean-Bernard, Falchero, Lionel, Veillon, Remi, Vieillot, Sabine, Guisier, Florian, Marcq, Marie, Justeau, Grégoire, Bigay-Game, Laurence, Bernardi, Marie, Doubre, Hélène, Pinsolle, Julian, Amrane, Karim, Chouaïd, Christos, Descourt, Renaud |
| المصدر: |
Journal of Immunotherapy ; volume 47, issue 1, page 16-20 ; ISSN 1524-9557 |
| بيانات النشر: |
Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: |
2023 |
| الوصف: |
Outside clinical trials, few data are available on the effect of long-term first-line pembrolizumab in patients with advanced non–small-cell lung cancers with ≥50% of tumor cells expressing programmed cell death ligand 1 (PD-L1). This French, multicenter study included consecutive advanced patients with non–small-cell lung cancer given first-line pembrolizumab alone between May 2017 (authorization date for this indication) and November 2019 (authorization date for pembrolizumab–chemotherapy combination). Information was collected from patients’ medical files, with a local evaluation of the response and progression-free survival (PFS). Overall survival (OS) was calculated from pembrolizumab onset using the Kaplan-Meier method. The analysis concerned 845 patients, managed in 33 centers: median age: 65 (range: 59–72) years, 67.8% men, 78.1% Eastern Cooperative Oncology Group performance status 0/1, 38.9%/51.5%/6.6% active, ex or never-smokers, respectively, 10.9%/16.8% taking or recently took corticosteroids/antibiotics, 69.6% nonsquamous histology, 48.9% ≥75% PD-L1–positive, and 20.8% had brain metastases at diagnosis. After a median (95% CI) follow-up of 45 (44.1–45.9) months, respective median (95% CI) PFS and OS lasted 8.2 (6.9–9.2) and 22 (8.5–25.9) months; 3-year PFS and OS rates were 25.4% and 39.4%, respectively. Multivariate analysis retained never-smoker status, adenocarcinoma histology, Eastern Cooperative Oncology Group performance status ≥2, and neutrophil/lymphocyte ratio >4 as being significantly associated with shorter survival, but not brain metastases at diagnosis or <75% PD-L1 tumor-cell expression. These long-term results of pembrolizumab efficacy based on a nationwide “real-world” cohort reproduced those obtained in clinical trials. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1097/cji.0000000000000490 |
| DOI: |
10.1097/CJI.0000000000000490 |
| الإتاحة: |
https://doi.org/10.1097/cji.0000000000000490Test |
| رقم الانضمام: |
edsbas.D32D2F70 |
| قاعدة البيانات: |
BASE |
